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Background: Porcine reproductive and respiratory syndrome virus (PRRSV) continues to be an important problem
for the swine industry. Inactivated vaccines and modified-live virus vaccines are widely used in the field; however,
the efficacy of these PRRSV vaccines is suboptimal due to poor immunogenicity. Granulocyte–macrophage colony
stimulating factor (GM-CSF) has been extensively used as an effective genetic and protein adjuvant to enhance the
efficiencies vaccines expressing tumor or pathogen antigens. The purpose of this study was to determine if GM-CSF
could increase the efficiency of PRRSV vaccine.
Methods: The GM-CSF gene was inserted in the HuN4-F112 vaccine strain by overlap PCR. The expression of
GM-CSF by the recombinant virus was confirmed with methods of indirect immunofluorescent assay (IFA) and
Western blotting. The stability of recombinant virus was assessed by cDNA sequence and IFA after 20 passages.
To detect the biological activity of GM-CSF expressed by the recombinant virus, bone marrow-derived dendritic
cells (BMDCs) were isolated and co-cultured with the recombinant virus or parental virus and the surface phenotypes
of BMDCs were examined by flow cytometric analysis. The cytokines secreted by BMDCs infected with PRRSV,
or treated with LPS, GM-CSF or medium alone were evaluated by ProcartaPlexTM Multiplex Immunoassays
and qRT-PCR.
Results: A novel modified-live PRRSV vaccine strain expressing GM-CSF (rHuN4-GM-CSF) was successfully
constructed and rescued. The GM-CSF protein was stable expressed in recombinant virus-infected cells after 20
passages. Analysis of virus replication kinetics showed that the novel vaccine strain expressing GM-CSF had a similar
replication rate as the parental virus. In vitro studies showed that infection of porcine BMDCs with rHuN4-GM-CSF
resulted in increased surface expression of MHCI+, MHCII + and CD80/86+ that was dependent on virus expressed
GM-CSF. The expression of representative cytokines was significantly up-regulated when BMDCs were incubated
with the recombinant GM-CSF expressing virus.
Conclusions: Our results indicated that the expression of GM-CSF during infection with a vaccine strain could
enhance the activation of BMDCs and increase cytokine response, which is expected to result in higher immune
responses and may improve vaccine efficacy against PRRSV infection.
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Porcine reproductive and respiratory syndrome (PRRS)
is a respiratory disease of pigs, and infects porcine of all
ages. PRRS causes reproductive failure in breeding swine.
PRRS was first described in North America in 1987 and
become responsible for major economic losses to the
swine industry [1]. The causative agent of PRRS is PRRS
virus (PRRSV), which is an enveloped positive-strand
RNA virus and belongs to the family of Arteriviridae
[2]. PRRSV is monocytotropic, which directly infects
subsets of macrophages and DCs and subverts overall
immune responses [3].
In 2006, a highly virulent strain of PRRSV (HP-PRRSV),
which caused significant morbidity can be characterized
by high fever, was first detected in China and then ra-
pidly spread to most provinces of China [4-6]. Under
these circumstances, vaccination against PRRSV pro-
vides invaluable support to increase host resistance,
reduce environmental contamination, and reduce the
chance of regional outbreaks. Two types of PRRSV vac-
cines are now available commercially: an inactivated
vaccine and the modified-live virus vaccine. Several live
attenuated North American-lineage PRRSV vaccines,
such as Ingelvac1 ATP, RespPRRS MLV, RespPRRS/
Repro1 ATP, and CH-1R, have been successfully employed
in field [7], and induce higher protection rates than with
inactivated vaccines. To respond to the recently emerged
HP-PRRSV, new live attenuated vaccines were developed
by passaging HP-PRRSV isolates in MARC-145 cell
lines [7-9].
The currently available modified live vaccines have
shown the most promising efficacy, however, there are
imperative issues that need to be addressed. Some ex-
amples are the partial protection against heterologous
viruses [10], delayed and suboptimal cell-mediated
immunity (CMI) and neutralizing antibody levels after
vaccination [11-13].
In an effort to develop more efficacious vaccines that
induced broader immune responses and protection
against heterologous PRRSV strains, live virus-vectored
vaccines were made by expressing immune response-
specific molecules [14,15]. Recruitment and activationFigure 1 Construction of the plasmid HuN4-GM-CSF. Porcine GM-CSF a
(TRS6) were inserted between ORF1b and ORF2 of the infectious molecularof dendritic cells (DCs) plays an important role in both
innate and adaptive immune responses to viral infec-
tions, including vaccination with live attenuated vaccines
[14,16]. GM-CSF as one of the most important cyto-
kines, has been used to differentiate DCs from mono-
cytes and bone marrow cells [17], as well as to mature
and/or activate DCs in vitro and in vivo [14,18,19].
Therefore, GM-CSF has been widely employed as an
attractive adjuvant to apply in therapeutic treatment
and in vaccine formulations [14,16,20-25]. In this study,
we constructed a recombinant PRRSV expressing GM-
CSF, and provide evidence that this recombinant vaccine
effectively activated DCs and regulate the anti-virus
microenvironment in vitro.
Results
Construction and rescue of the recombinant PRRSV
Pei et al [26] and Lawson SR et al [15] showed that the
position between ORF1b and ORF2 of PRRSV is a suit-
able site for foreign gene insertion [15,26]. In this study,
the GM-CSF gene and the synthesized TRS6 sequence
were inserted between the stop codon of ORF1b and the
start codon of ORF2 of the infectious molecular clone of
HuN4-F112 vaccine strain by overlap PCR (Figure 1).
The full-length cDNA clone pHuN4-GM-CSF was veri-
fied by nucleotide sequencing (as described in Materials
and Methods). The recombinant virus rHuN4-GM-CSF
was rescued by transfecting BHK-21 cells (Baby ham-
ster Kidney cells clone 21) with plasmid expressing
the recombinant virus and passaging of the superna-
tants in MARC-145 cells. Cytopathic effects (CPE) were
observed on MARC-145 cells 3 days post-infection
(Figure 2A to C). As shown in Figure 2D, the RT-PCR
fragment derived from the recombinant virus was cleaved
by restriction enzyme Mlu I, generating two fragments
of 360 bp and 92 bp (lane 1). In contrast, no cleaved
fragment was detected in the PCR amplification prod-
ucts derived from the parental isolate virus under the
digestion of Mlu I (lane 2). Sequence determination of
inserted GM-CSF gene confirmed that the recombinant
virus rHuN4-GM-CSF was successfully generated (data
not shown).nd a copy of the transcription regulatory sequence for PRRSV ORF6
clone of the HuN4-F112 vaccine strain by overlap PCR.
Figure 2 Rescue of the recombinant PRRSV. Cytopathic effects (CPE) were observed on MARC-145 cells after infection by viruses for 3 days.
CPE was observed in rHuN4-GM-CSF (A) and HuN4-F112 (B), while mock-infected cells remained normal (C) Original Magnification 100×.
(D) Identification of the recombinant virus and parental virus with genomic marker. The presence of a Mlu I restriction site in recombinant virus
resulted in fragments of 360 bp and 92 bp. (1) rHuN4-GM-CSF; The RT-PCR fragments derived from the parental isolate was not digested by
Mlu I (2) HuN4-F112; (M) Marker DL2000.
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We next investigated whether the inserted GM-CSF
gene could be expressed in recombinant PRRSV-infected
cells. As expected, mouse anti-GM-CSF monoclonal
antibody (mAb) specifically detected the MARC-145
cells infected with rHuN4-GM-CSF in IFA (Figure 3A),Figure 3 Expression of GM-CSF by rHuN4-GM-CSF. Cells were infected
24 hours before analysis. (A) The virus-infected MARC-145 cells were fixed
porcine GM-CSF. Original Magnification 200×. (B) Western blot detection o
MARC-145 cells infected with viruses.but not cells infected with the HuN4-F112 control virus.
As shown in Figure 3B, the expression of GM-CSF pro-
tein (22 kDa) was detected in the supernatant and cell
lysates of MARC-145 cells that infected with the recom-
binant rHuN4-GM-CSF, but not the parental virus, by
Western blotting using anti-porcine GM-CSF mAb.at a multiplicity of infection (MOI) of 1 with viruses and incubated for
and tested by IFA to determine the expression of PRRSV N protein and
f GM-CSF in the supernatant fraction (sup) or cell lysates (cell lys) of
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the GM-CSF gene
To investigate whether the inserted gene could be stably
maintained in the recombinant virus, we serially passaged
the virus on MARC-145 cells to 20 times. The GM-CSF
gene encoded by the recombinant PRRSV was detected by
PCR amplification (Figure 4A) and confirmed by Sanger
sequencing (data not shown). Consistent with the previous
IFA data, the expression of GM-CSF by MARC-145 cells
infected with the recombinant virus could be detected by
IFA after 20 passages (Figure 4B).
The viral replication kinetics of the recombinant virus
and the parental control were examined in MARC-145
cells to determine if the insertion of the GM-CSF se-
quence or if GM-CSF expression by virus-infected cells
had an impact on viral replication. The supernatants
from cells infected with recombinant virus or parental
virus was collected at 12, 24, 36, 48, 60, 72 and 84 hpi
for virus titration. As evidenced by the viral titers, the
replication kinetics of the recombinant rHuN4-GM-CSF
was very similar to that of the parental virus (Figure 4C).
The plaque morphology and size of rHuN4-GM-CSF on
MARC-145 cells were also similar to that of the parental
virus (Figure 4D). These results indicated that the inser-
tion or expression of the GM-CSF gene did not affect
the growth rate of the HuN4-F112 vaccine strain.Figure 4 Characterization of the recombinant PRRSV expressing the G
insertion in the recombinant virus. F was product of the parental virus; the
DL2000. The recombinant viruses used in B, C and D were passaged in MA
expression in recombinant virus-infected MARC-145 cells by IFA. Original M
GM-CSF and the parental virus in MARC-145 cells. The infection was done
indicated time points and titrated in MARC-145 cells. (D) Plaque assays for
viruses were stained with crystal violet at 4 days post infection.Maturation and activation of BMDCs stimulated by
rHuN4-GM-CSF
To test the biological activity of GM-CSF expressed by
the recombinant virus, BMDCs were isolated from por-
cine bone marrow, and co-cultured with the recombinant
virus or parental virus. BMDCs treated with lipopolysac-
charide (LPS) were included as a positive control. BMDCs
were infected with PRRSV at MOI of 0.03 and the surface
phenotypes of these cells were examined by flow cyto-
metric analysis at 48 hpi. As shown in Figure 5A, infec-
tion with rHuN4-GM-CSF promoted better maturation
and/or activation of BMDCs than infection with the
parental virus, when they were pretreated with GM-CSF,
as shown by significantly more MHC I+/CD 80/86+ and
MHC II+/CD 80/86+ double positive cells.
On the other hand, BMDCs without prior treatment
of GM-CSF were incubated with PRRSV at MOI of 0.3
and the surface phenotype expressions of MHC I, MHC
II and CD 80/86 were evaluated by flow cytometry at 48
and 72 hpi. LPS and GM-CSF individually were as posi-
tive control. As expected, rHuN4-GM-CSF induced more
MHC I+/CD 80/86+ and MHC II+/CD 80/86+ doubly po-
sitive cells than the parental virus (Figure 5B and C). As a
negative control, very few GM-CSF-treated or non-treated
BMDCs were activated by the medium alone. These
results indicated that the rHuN4-GM-CSF expressingM-CSF gene in MARC-145 cells. (A) Detection of the GM-CSF gene
numbers show the passages of the recombinant viruses; M was Marker
RC-145 cells for 20 passages. (B) Detection of GM-CSF protein
agnification 200×. (C) Growth kinetics comparison between rHuN4-
as mentioned above. The cell supernatants were harvested at the
the parental virus and rHuN4-GM-CSF. MARC-145 cells infected with
Figure 5 Maturation and activation of BMDCs stimulated by rHuN4-GM-CSF. BMHCs as DC precursors were cultured with or without
GM-CSF. The cells were infected with viruses. LPS and GM-CSF were used as a positive control, and the medium from untreated cells (Mock)
served as a negative control. Maturation of BMDCs treated by GM-CSF and then inoculated virus at 48 hpi (A). Activation of BMDCs were cultured
without GM-CSF, but directly infected with viruses at 48 hpi (B) and 72 hpi (C). All data are the means from three independent experiments with
cells from different donors. The horizontal lines represent the geometric mean for each group, and statistical analysis was performed. *: P < 0.05;
**: P < 0.01.
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tor cells to DCs in vitro.
Cytokines secreted by BMDCs treated with rHuN4-GM-CSF
The cytokines secreted by BMDCs infected with PRRSV,
or treated with LPS, GM-CSF or medium alone were
as evaluated by ProcartaPlex™ Multiplex Immunoas-
says. As shown in Figure 6A, B and D, a significantly
higher level of IL-1β, IL-12 and IFN-γ were observed
for rHuN4-GM-CSF infected BMDCs compared to
that of cells infected with the parental virus from 24
to 96 hpi. Despite the low levels, we detected slightly
higher expression of IL-4 and TNF-α in BMDC trea-
ted by rHuN4-GM-CSF than treated by the parental
virus (Figure 6C and E).
In addition, qRT-PCR was performed to measure
mRNA expression level of GM-CSF, IL-1β, IL-4, IL-12,
IFN-γ and TNF-α at 24, 48, 72 and 96 hpi. As shown in
Figure 7, the mRNA expression level of GM-CSF was
significantly higher in rHuN4-GM-CSF infected BMDCs
than that of cells infected with the parental virus until
48 hpi (Figure 7A). The expression of IL-1β in BMDCs
infected with rHuN4-GM-CSF was significantly higher
than that infected with the parental virus until 96 hpi
(Figure 7C). The expression of IL-12, IL-4 and IFN-γ
was also higher than other groups at 24 hpi (Figure 7B,
C and D). Our data suggested that the recombinant
virus expressing GM-CSF, a DC-stimulating molecule,
activated DCs and induced higher levels of cytokines
expression.Discussion
PRRSV is one of the most economically significant viral
pathogens for pig production worldwide. PRRSV in-
fection could impair the ability of APCs to stimulate
antigen-specific immune responses, dysregulate expres-
sion of various inflammatory cytokines, which could dis-
rupt the establishment of an anti-virus microenvironment
in vivo. Vaccines are widely used to control PRRSV; how-
ever, these vaccines can result in immunosuppression and
confer limited heterologous protection [11-13]. As one of
the most efficient adjuvants, GM-CSF has been widely
studied to enhance the immunogenicity of tumor and pa-
thogen antigens [14,16,20-25]. Here, we successfully gen-
erated a recombinant PRRSV virus expressing GM-CSF,
rHuN4-GM-CSF, and demonstrated in vitro that rHuN4-
GM-CSF has the potential to be a more efficient candidate
vaccine.
Previous studies proved that PRRSV could tolerate the
addition of foreign genes, which were fused to ORF1b,
ORF7, or Nsp2 [27-31]. However, insertion of extra non-
viral genes has reduced levels of replication or resulted
in genetic instability such that the recombinant viruses
no longer encode a functional foreign gene after serial
passage. TRS has been reported to drive transcription of
the inserted gene without affecting expression of virus
genes in recombinant PRRSV [15,26,28]. Moreover, pre-
vious studies showed that GM-CSF is a safe and effica-
cious adjuvant for enhancing the viral specific immune
response and has been investigated in several viral vectors,
such as vesicular stomatitis virus (VSV) [25], retrovirus
Figure 6 Cytokines secreted by BMDCs treated with rHuN4-GM-CSF. The expression of cytokines determined by ProcartaPlexTM Multiplex
Immunoassays. BMDCs were incubated with either rHuN4-GM-CSF or the parental virus at MOI of 0.3 at 24, 48, 72 and 96 hpi. LPS and GM-CSF
were used as a positive control, and the medium from untreated cells (Mock) served as a negative control. (A) IL-1β; (B) IL-12; (C) IL-4; (D) IFN-γ;
(E) IFN-α. The horizontal lines represent the geometric mean for each group, and statistical analysis was performed. *: P < 0.05; **: P < 0.01.
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combinant Rabies virus (RABV) expressing GM-CSF en-
hanced the immunogenicity of RABV via recruitment
and activation of DCs and B cells in the draining lymph
nodes [14,16]. Therefore, we generated the recombinant
virus rHuN4-GM-CSF by inserting the GM-CSF between
ORF1b and ORF2 using the original TRS2 to drive trans-
cription of GM-CSF and inserting an extra synthetic TRS6
to drive transcription of the ORF2 genes. This recombin-
ant virus showed similar replication ability as compared to
the parent PRRSV vaccine strain. Furthermore, the recom-
binant virus stably expressed GM-CSF following 20 pas-
sages in MARC-145 cells.
It is known that GM-CSF regulates Th1 and Th2 im-
mune responses by activation and maturation of DCs,
DCs are the most efficient APCs and thus play a key role
in both innate and adaptive immune responses in vivo
[32]. Furthermore, mature and activated DCs are critical
to the activation of T cells and virus-specific adaptive
immune responses [33]. When porcine bone marrow he-
matopoietic cells (BMHCs) were stimulated with GM-
CSF, three types of myeloid cells were generated: ad-
herent macrophages, non-adherent granulocytic cells and
BMDCs. The adherent macrophage cells expressed lowerlevels of both MHC II and CD80/86 compared to BMDCs.
BMDCs, as the dominant cell type, were MHC IIhigh
CD80/86+ whereas granulocytic cells were MHCII¯/low
[34,35]. MHC II molecules are expressed only on APCs.
T cells that recognize only antigenic peptides displayed
with MHC II generally function as T helper cells. In the
study, as expected, rHuN4-GM-CSF induced more MHC
II+/CD 80/86+ doubly positive cells than the parental virus
(Figure 5) in vitro. Thus, mature and activated DCs are
critical to the activation of T cells and virus-specific
adaptive immune responses. In addition, MHC I mole-
cules are expressed on nearly all nucleated cells. The
cell-mediated immune response to viral infections is
the presentation of virus-encoded peptides by MHC I
molecules to T cytotoxic cells [36]. BMDCs could be
infected by PRRSV [37]. In the study, results show that
rHuN4-GM-CSF induced more MHC I+/CD 80/86+
doubly positive cells than the parental virus (Figure 5).
The up-regulated expression of MHC I molecules of
BMDCs allows the virus to evade detection and des-
truction by cytotoxic T-cells. Furthermore, the recom-
binant rHuN4-GM-CSF vaccine would trigger stronger
cell-mediated immune response to viral infections than
the parental HuN4-F112 vaccine in vivo.
Figure 7 Quantification of cytokines of BMDCs by qRT-PCR. BMDCs were incubated with either rHuN4-GM-CSF or the parental virus at MOI
of 0.3 at 24, 48, 72 and 96 hpi. LPS was used as a positive control, and the medium from untreated cells (Mock) served as a negative control. Total
RNA was prepared and used in a qRT-PCR to determine levels of mRNA levels for cytokines. (A) GM-CSF; (B) IL-12; (C) IL-1β; (D) IFN-γ; (E) IL-4;
(F) IFN-α. The horizontal lines represent the geometric mean for each group, and statistical analysis was performed. *: P < 0.05; **: P < 0.01.
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IL-1β, IL-4 (Th2) and IFN-γ (Th1) were produced fol-
lowing infection of BMDCs with the recombinant virus
than with the control virus. Previous studies proved that
Th1 responses are characterized by the development of
antigen-specific IFN-γ-secreting T cells [38] and IFN-γ
promotes co-stimulatory molecule and pro-inflammatory
cytokines production (such as IL-1 and IL-12) [39,40]. Of
particular interest, IL-12 is a heterodimeric cytokine that
is produced mainly by activated myeloid DCs and plays a
pivotal role in the differentiation and expansion of Th1
cells [41,42]. In this study, the recombinant virus could in-
duce the higher mRNA and protein levels of IL-12 in
BMDCs, compared to the parent live-attenuated virus.
High expression of IL-12 by DCs augments NK cells and
T cells mediated cytotoxicity and stimulate production of
IFN-γ and proliferation of NK cells and T cells as well
[43-45]. The increased levels of cytokines production
following rHuN4-GM-CSF virus infection would likely
improve the ability of APCs to stimulate antigen-specific
immune responses and regulate the anti-virus micro-
environment. Base on this research, GM-CSF may be an
effective adjuvant expressed by recombinant virus. DCs
play a critical role in the development of both protective
and pathogenic aspects of antiviral immunity. Upon the
addition of IFN-γ, there would be maturation and activa-
tion of DCs and high-level release of IL-12[46,47]. Mye-
loid DCs are also target of Dengue virus and Measles
virus. It would be used to develop new vaccines andtherapeutic strategies by construction recombinant atten-
uated viruses expressing molecular adjuvants.
Conclusions
In summary, the recombinant virus expressing GM-CSF
was successfully constructed and rescued. The GM-CSF
gene was stably expressed and did not affect the replica-
tion phenotype of the parent virus. Importantly, in vitro
results showed that rHuN4-GM-CSF enhance the activa-
tion of DCs and promoted the secretion of several cyto-
kines. These results demonstrated that the recombinant
virus expressing GM-CSF holds great promise and is
likely to be a more efficacious PRRSV candidate vaccine.
Materials and methods
Virus strains and cell lines
HuN4-F112, an attenuated vaccine virus strain adapted
from the highly pathogenic PRRSV (HP-PRRSV) HuN4
strain (GenBank accession no. EF635006), was propaga-
ted and titrated in MARC-145 cells (African green mon-
key kidney cell line) [9]. BHK-21 cells were used to rescue
virus by transfection with in vitro transcribed viral RNA.
Construction of PRRSV expressing GM-CSF
Sequences that correspond to GenBank (U67175.1) and
encode porcine GM-CSF protein were synthesized in our
laboratory. The sequence encoding GM-CSF with signal
peptide inserted between ORF1b and ORF2 in the infec-
tious molecular clone of the HuN4-F112 vaccine strain by
Table 1 Primers uesd for construction of recombinant PRRSV infectious clones
Primer Nucleotide sequence (5′–3′) Sense Relative position in
the genome
F1 TTCCGGAGACAGTCTTCAGC + 11143bp-11162bp
R1 TTCTGCAGCCACATTTCAATTCAGGCCTAAAGTT - 11963bp-11982bp
F2 AACTTTAGGCCTGAATTGAAATGTGGCTGCAGAA + 11963bp-11982bp
R2 TTGCATAGACCCCATTTCATCGTTCCGCTGAAACTCTGGTTAAAGGGGTTGCCGCGGAACTTACTTTTTGACTG - 11983bp-12002bp
F3 GTTTCAGCGGAACGATGAAATGGGGTCTATGCAA + 11983bp-12002bp
R3 GAAAGGCCTCATAAGATCTTCT - 12196bp-12217bp
Bold letters (nucleotides) in sequences denote the restriction enzyme sites (F1-BspE I;R3-Bgl II), and the italics in the sequence indicate the transcription-regulating
sequence 6 of PRRSV(TRS6).
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clone, pHuN4-GM-CSF. The primers used for overlap
PCR are described in Table 1. The expression of GM-CSF
in the construct was controlled by the transcription-
regulating sequence 2 (TRS2) for ORF2, and an extra syn-
thetic transcription-regulating sequence 6 (TRS6) derived
from ORF6 was inserted downstream of the GM-CSF
gene to drive the expression of ORF2. Hence, GM-CSF is
expressed from an independent subgenomic RNA.
To rescue the virus, capped RNAs of the viral genome
produced by in vitro transcription reactions with the
recombinant clone were transfected into BHK-21 cells
[48]. The rescued recombinant viruses were propagated
in MARC-145 cells, which were maintained in DMEM
with 10% heat-inactivated fetal bovine serum (Life
Technologies, Switzerland). The infected MARC-145
cells were monitored daily for the formation of cyto-
pathic effect (CPE). Rescued recombinant virus RNAs
were extracted from cell culture supernatants of the in-
fected cells by using an RNeasy Plus Mini kit (QIAGEN).
RT-PCR was performed as described previously. And
the RT-PCR amplified product was digested by Mlu I
to check the genetic marker engineered into the recom-
binant virus [48].
GM-CSF gene expression by the recombinant virus
was confirmed by methods of indirect immunofluorescent
assay (IFA) and Western blotting. For IFA, MARC-145
cells were infected with the virus at MOI of 1. The pri-
mary antibodies used were specific monoclonal antibodiesTable 2 Primers uesd for amplifying cytokines
Gene Upper primer (5′–3′)
GAPDH ATG GTG AAG GTC GGA GTG AA
GM-CSF AAG CCC TGA GCC TTC TAA ACA
IL-1β GCC CCA AAG AGA TGA AGT GC
IL-4 GCA CAT CTA CAG ACA CCA CA
IL-12 GCC TGC TTA CCA CTT GAA CT
IFN-γ GCT CTG GGA AAC TGA ATG AC
TNF-α ACC ACG CTC TTC TGC CTA CTagainst PRRSV nucleocapsid protein [49] and porcine
GM-CSF (R&D systems, MN), respectively. The secondary
antibodies were Alexa Fluor®488 donkey anti-mouse IgG
(H + L)(For GM-CSF detection) and Alexa Fluor®568
goat anti-mouse IgG (H + L)(for N protein detection)
(Life Technologies, Switzerland). To confirm synthesis
of GM-CSF recombinant protein from rHuN4-GM-CSF
in MARC-145 cells, the culture supernatant and cells were
collected and analyzed by Western blotting. Monoclonal
antibody against porcine GM-CSF and anti-β-actin anti-
body (Sigma-Aldrich) were used as primary antibodies.
Primary antibody reactivity was visualized using a chemio-
luminescence detection system (Thermo Fisher Scientific).
Confirming the inserted gene within the recombinant
virus
To assess the stability of the insert in recombinant virus,
the rescued virus was serially passaged in MARC-145
cells for twenty times. At the 5th, 10th, 15th, and 20th
passages, the inserted gene was amplified by RT-PCR
and the cDNA sequenced.
Characterization of rHuN4-GM-CSF after 20 passages in
MARC-145 cells
After the recombinant virus was passaged 20 times, the
expression of the inserted gene was detected by IFA as
described above. To investigate the growth property of
the recombinant virus, MARC-145 cells cultured in 6-well
plates were inoculated with an infection dose at MOI ofLower primer (5′–3′)
C CGT GGG TGG AAT CAT ACT GG
GGT CAA ACA TTT CAC AGA CGA
T TCC ACT GCC ACG ATG ACA GA
C CTT TAG CCT TTC CAA GAA GTC
GCA CAG GGT TGT CAT AAA AGA G
T TGA CTT CTC TTC CGC TTT CTT A
GGC TTT GAC ATT GGC TAC AAC
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60, 72 and 84 hours post infection (hpi), and titrated by
the method of Reed-Muench on MARC-145 cells in
96-well plates. Plaque morphology of the virus was de-
termined by plaque assay. The recombinant rHuN4-
GM-CSF virus and its corresponding parental virus were
serially diluted 10-fold, and then added to MARC-145
cells in 6-well plate for 1 hour at 37°C. Plaques were
stained at 37°C with crystal violet 3-5 days post infection.
Generation of porcine bone marrow-derived dendritic
cells (BMDCs)
BMDCs were isolated as described previously [34,50].
Briefly, BMHCs were harvested by flushing the bone
marrow of the femur and tibia of 6-week old piglets with
phosphate-buffered saline (PBS). Red blood cells were
lysed with ACK lysis buffer containing 0.15 M NH4Cl,
10 mM KHCO3 and 0.1 mM Na2EDTA. BMHCs were
washed twice with PBS, and cultured at 2 × 106 cells/
dish in 10 ml RPMI 1640 supplemented with Penicillin
(100 U/ml, Gibco), Streptomycin (100 mg/ml, Gibco), L-
glutamin (2 mM, Sigma), 2-mercaptoethanol (50 mM,
Sigma), 10% heat-inactivated FBS (Gibco) and GM-CSF
(20 ng/ml, R&D systems). After three days, another 10
ml of complete culture medium containing 20 ng/mL
GM-CSF was added. At one week, non-adherent cells
were collected.
Flow cytometric analysis
Phenotypic analysis was performed by direct immuno-
fluorescence staining in FACS buffer (DPBS containing
3% heat-inactivated FBS and 0.09% NaN3). Single-cell
suspensions were stained with anti-CTLA-4-PE (Ancell),
anti-MHC I-FITC (SLA CLASS I, Serotec) and anti-
MHC II-FITC (SLA CLASS II, Serotec) in FACS buffer
for 45 minutes on ice, and then washed twice with FACS
buffer. The cells were analyzed on a Beckman FC500
flow cytometer with FlowJo software (TreeStar, San
Carlos, CA).
Quantification of Cytokines by RT-qPCR and Multiplex
Immunoassays
To analyze the characteristics of BMDCs, cytokine as-
says were performed using ProcartaPlexTM Multiplex
Immunoassays (Affymetrix, eBioscience) according to
the manufacturer’s instructions. Briefly, BMDCs were in-
cubated with rHuN4-GM-CSF or the parental virus at
MOI of 0.3, and the supernatant was harvested at 24, 48,
72 and 96 hpi. The collected supernatants were incu-
bated with Antibody Magnetic Beads in the individual
wells of a 96-well plate for overnight. Each sample was
plated in duplicate. Next, 25 μl of Detection Antibody
was added to each well and then the plate was incubated
for a further 30 min. Streptavidin Phycoerythrin solutionwas added to each well (50 μl per well). After 30 minutes
incubation, the plate was read by a Luminex xMAP 200
analyzer (Luminex Corporation). The cytokine concen-
trations were extrapolated from standard curves using
Xponent software (Luminex Corporation).
At the same time, BMDCs were collected at the indi-
cated time points post infection for mRNA extraction
using the RNeasy Mini kit (Qiagen, Hilden, Germany).
cDNA was synthesized with Oligo (dT)18 primers and
ReverAid First Strand cDNA Synthesis kit (Thermo sci-
entific) and quantified by real-time(RT) SYBR green
PCR assay was carried out with a StepOnePlus (Life
Technologies, USA). The gene expression profile for cy-
tokines, GM-CSF, IL-1β, IL-4, IL-12, IFN-γ and TNF-α
were quantified and normalized with the housekeeping
gene GAPDH. The primers used for these assays are
described in Table 2.
Statistical analysis
Figures and statistical analyses were completed with
GraphPad Prism V.5 software (GraphPad Software, San
Diego, California, USA). The statistical significance of the
differences among group values was determined using
one-way analysis of variance (ANOVA).
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